Occurrence and outcome of COVID-19 in AIRD patients on concomitant treatment with Tofacitinib- results from KRA COVID COHORT (KRACC) subset
Abstract Introduction We assessed the risk factors and outcome of COVID-19 in patients with autoimmune rheumatic diseases(AIRD) who contracted infection while on background treatment with tofacitinib. Methods This is a non-interventional, cross-sectional, questionnaire based telephonic study which i...
Main Authors: | Pramod Chebbi, Vineeta Shobha, Vijay K Rao, Vikram Haridas, Ramya Janardana, Benzeeta Pinto, Sharath Kumar, Abhishek Patil, Roopa Tekkatte, Manasa Salanke, K M Mahendranath |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-07-01
|
Series: | BMC Rheumatology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41927-023-00345-8 |
Similar Items
-
Tofacitinib
by: Nilgün Şentürk
Published: (2022-04-01) -
Tofacitinib: Revisión
by: Carlos Ríos Acosta, et al.
Published: (2016-12-01) -
Acne exacerbation after tofacitinib treatment for alopecia areata
by: Sawsan Alharthi, et al.
Published: (2021-10-01) -
Tofacitinib in a Recalcitrant Case of Alopecia Areata
by: Mansi Pithadia, et al.
Published: (2022-12-01) -
Tofacitinib in Hypertrophic Lichen Planus
by: Peter Seiringer, et al.
Published: (2020-07-01)